Targeted drug may shrink thyroid tumors before surgery
NCT ID NCT01709292
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 29 times
Summary
This study tests the drug vemurafenib in 24 people with advanced papillary thyroid cancer that has spread or cannot be easily removed. The drug blocks a specific gene mutation (BRAF) that fuels cancer growth. Researchers measure how much tumors shrink and how biomarkers change after 56 days of treatment, aiming to make surgery safer or even possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.